Enhancement of immunohistochemical reactivity for thymidine phosphorylase in breast carcinoma cells after administration of docetaxel as a neoadjuvant chemotherapy in advanced breast cancer patients

Oncology Reports

Volumn 7, Issue 5, 2000, Pages 945-948

  Kurosumi, Masafumi ^a  

^a SAITAMA CANCER CENTER   (Japan)

Author keywords

Breast neoplasm; Docetaxel; Immunohistochemistry; Neoadjuvant chemotherapy; Thymidine phosphorylase

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; DRUG DERIVATIVE; KERATIN; PACLITAXEL; TAXOID; THYMIDINE PHOSPHORYLASE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST TUMOR; CANCER STAGING; CLINICAL TRIAL; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED;

ADULT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; TAXOIDS; THYMIDINE PHOSPHORYLASE;

EID: 0034265883     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.5.945     Document Type: Article

References (1)

1. Ravdin PM, Burris HA III, Cook G, Eiscnberg P, Kane M, Bierman WA, Mortimer J, Genevois E and Bellet RE: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13: 2879-2885, 1995.